Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention

10Citations
Citations of this article
80Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Current oral antiretroviral agents provide highly effective treatment for patients infected with human immunodeficiency virus (HIV), and can be used as pre-exposure prophylaxis (PrEP) to prevent new HIV infections. Several single-tablet regimens with excellent antiviral efficacy have dramatically improved the quality of life of patients who can adhere to daily oral therapy. However, there is increasing demand on long-acting injectable antiretroviral agents for patients who cannot take oral agents or feel fatigue related to daily pill burden. Monthly long-acting (LA) cabotegravir (CAB) combined with rilpivirine (RPV) has recently been listed as optimizing agent for maintenance of HIV suppression in treatment-experienced patients whose viral load is undetectable for 3 to 6 months. Novel agents with different mechanism of action and long half-life extending dosing interval are being tested in phase 2 and 3 clinical trials. This review summarizes the data of efficacies and safety profiles of LA CAB with RPV regimen, and also new long-acting injectable antiretroviral agents in pipeline.

Cite

CITATION STYLE

APA

Kim, Y. S. (2021, December 1). Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention. Infection and Chemotherapy. Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, Korean Society for AIDS. https://doi.org/10.3947/ic.2021.0136

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free